Updated Jul 16, 2026
Plavsic Mark is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $230K.
Mark Plavsic is the Chief Technology Officer at Aura Biosciences, Inc., a clinical-stage biotechnology company focused on developing precision immunotherapies for solid tumors. He has been involved in the company's operations as it advances its clinical candidates.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-03 | AURA | Aura Biosciences, Inc. | A — Grant or award | 62.3K | $0.00 | |
| 2026-02-18 | AURA | Aura Biosciences, Inc. | S — Open-market sale | 15.9K | $5.05 | $80K |
| 2025-10-16 | AURA | Aura Biosciences, Inc. | S — Open-market sale | 12.2K | $6.35 | $77K |
| 2024-10-16 | AURA | Aura Biosciences, Inc. | S — Open-market sale | 7.4K | $9.85 | $73K |
Mark Plavsic is the Chief Technology Officer at Aura Biosciences, Inc., a clinical-stage biotechnology company focused on developing precision immunotherapies for solid tumors. He has been involved in the company's operations as it advances its clinical candidates.…
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($230K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Plavsic Mark profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.